Medical Devices US

US Digital Diabetes Management Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Digital Diabetes Management Market Industry Trends and Forecast to 2034: Segmented by (Product, Type, End-user, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Buy the full report

Report snapshot

US Digital Diabetes Management Market Analysis at a glance
Market size, 2025Researched figures come with the full report
Forecast, 2034Researched figures come with the full report
Growth (CAGR), 2025–2034Researched figures come with the full report
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, type and end-user (see all)
Key playersMedtronic, Abbott Laboratories, Dexcom, Inc., Roche Diabetes Care, Ascensia Diabetes Care and 5 more (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

The US Digital Diabetes Management Market Analysis Executive Summary

Digital Diabetes Management refers to the use of technology, including mobile applications, wearable devices, and telehealth services, to assist individuals in managing their diabetes effectively. This approach enables real-time monitoring of blood glucose levels, medication adherence, and lifestyle choices, providing personalized feedback and support. The global scenario for digital diabetes management is rapidly evolving, with a significant increase in the adoption of these technologies. According to a report by the American Diabetes Association, nearly 60% of adults with diabetes are using digital tools to manage their condition, reflecting a growing trend towards integrating technology into diabetes care.

The adoption of digital diabetes management solutions has been accelerated by the COVID-19 pandemic, which prompted many healthcare providers to establish virtual clinics. These clinics leverage digital data collected from devices to offer tailored treatment recommendations. Furthermore, advancements in artificial intelligence (AI) and data analytics are enhancing the effectiveness of these tools, allowing for more precise adjustments to treatment plans. As healthcare continues to embrace digital transformation, the shift towards digital solutions not only empowers patients but also supports healthcare providers in delivering more efficient and effective care.

US Digital Diabetes Management Market Dynamics

Market Growth Drivers

One of the most significant drivers is the perceived benefit of these technologies in improving diabetes control and patient outcomes. Research indicates that patients who recognize the advantages of using mobile health apps and digital tools, such as enhanced self-monitoring and personalized feedback, are more likely to adopt these solutions. Additionally, recommendations from healthcare professionals play a crucial role; when clinicians endorse the use of DDM tools, patients are more inclined to engage with them. A study found that younger, tech-savvy individuals are particularly receptive to adopting these technologies, further indicating that familiarity with digital tools enhances acceptance

Opportunity

Companies like Glyconics are developing needle-free diabetes testing using infrared technology, which could revolutionize blood sugar monitoring by providing quick and painless assessments. Additionally, Fractyl Health is innovating with its Revita procedure, which aims to improve blood glucose control through endoscopic techniques, showcasing a shift towards more holistic and minimally invasive treatments

Market Restraints

The adoption of Digital Diabetes Management faces notable challenges. Resistance to change among patients, particularly older adults or those with lower technological literacy can hinder uptake. A systematic review highlighted that individuals with less education and older age groups are less likely to utilize digital tools for diabetes management. Furthermore, concerns regarding data privacy and security can create apprehension among users, deterring them from engaging with DDM solutions. The lack of consistent recommendations from healthcare providers also contributes to this hesitancy

Competitive Landscape for Digital Diabetes Management Market in US

Key Players

Recent Developments

Jun 2024, DexCom, Inc. a global leader in real-time continuous glucose monitoring, has expanded its Automated Insulin Delivery (AID) partnership to the Netherlands. People with Type 1 diabetes in the Netherlands can now use the new tubeless Omnipod® 5 Hybrid Closed Loop (HCL) system, integrated with the Dexcom G6 CGM, for easier diabetes management

Jan 2024, Medtronic plc secured CE Mark approval for its MiniMed™ 780G system featuring the new Simplera Sync™ continuous glucose monitor (CGM). This advanced CGM requires no fingersticks or overtape, offers a simplified two-step insertion process, and is half the size of previous sensors

Healthcare Policies and Regulatory Landscape for Digital Diabetes Management Market in US

Digital Diabetes Management in the US: rules, payment and health figures

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure for the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

In the U.S., the Centers for Medicare & Medicaid Services (CMS) has expanded telehealth coverage, including remote diabetes monitoring, enabling healthcare providers to deliver care remotely and track patient data through digital tools. The FDA has also granted emergency use authorization for certain at-home diabetes devices, boosting Digital Diabetes Management (DDM) adoption during the pandemic. The reimbursement landscape is evolving, with more insurers covering continuous glucose monitors (CGMs) and other DDM tools, making them accessible to patients.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Digital Diabetes Management right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Digital Diabetes Management in context

The US compared

  • Diabetes (adults, WHO): 12.5% of adults (2022). World: 14.1% of adults (2022).[1]
  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[2]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[3]

[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

What segments does the Digital Diabetes Management market report cover?
The report splits the market by product (Devices, Digital Diabetes Apps), type (Wearable Devices, Handheld Devices) and end-user (Hospitals & Specialty Diabetes Clinics, Homecare Settings, Academic & Research Institutes, Self/Home Users).
Who are the key players in the Digital Diabetes Management market?
Key players include Medtronic, Abbott Laboratories, Dexcom, Inc., Roche Diabetes Care, Ascensia Diabetes Care and Tandem Diabetes Care, among 10 companies the report profiles.
What is driving the Digital Diabetes Management market?
One of the most significant drivers is the perceived benefit of these technologies in improving diabetes control and patient outcomes.
Who regulates Digital Diabetes Management in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
What does WHO report for the US?
Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 16 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on diabetes and digital health

See the topic